No ratings yet
Taught by or worked with Randall? Your rating helps other students choose.
Randall J. Bateman, MD, is the Charles F. and Joanne Knight Distinguished Professor of Neurology at Washington University in St. Louis. He serves as Director of the Dominantly Inherited Alzheimer Network (DIAN), Director of the DIAN Trials Unit (DIAN-TU), Principal Investigator of the Bateman Lab, and Director of the Tracy Family Stable Isotope Labeling Quantitation (SILQ) Center for Neurodegenerative Biology. Dr. Bateman treats patients with dementia at the WashU Medicine Memory Diagnostic Center. He received B.S. degrees in electrical engineering and biology from Washington University and an M.D. from Case Western Reserve University School of Medicine. He completed a neurology residency at Barnes-Jewish Hospital and postdoctoral research at Washington University School of Medicine.
Dr. Bateman’s research focuses on the pathophysiology and development of improved diagnostics and treatments of Alzheimer’s disease. His lab pioneered central nervous system Stable Isotope Labeling Kinetics (SILK) measurements in humans, advanced understanding of human circadian patterns of amyloid-beta and soluble amyloid precursor protein, and developed methods to quantify the pharmacodynamic action of drugs targeting amyloid-beta, amyloid precursor protein, and apolipoprotein E. The lab discovered the first high-precision blood test for Alzheimer’s disease amyloid plaques and has generated highly accurate blood tests that rival PET and CSF tests. Dr. Bateman launched the DIAN-TU Pharma Consortium and directs prevention trials in families with dominantly inherited Alzheimer’s disease. He holds 47 active or pending patents and co-founded C2N Diagnostics. Awards include the Beeson Award for Aging Research, Alzheimer’s Association Zenith Fellow’s Award, Scientific American top innovator recognition, Glenn Award for Aging Research, Washington University Chancellor’s Award for Innovation and Entrepreneurship, MetLife Foundation Award for Medical Research, Potamkin Prize, and CTAD Lifetime Achievement Award in Alzheimer’s Disease Therapeutic Research. He is an elected member of the National Academy of Medicine and the National Academy of Inventors, and a member of the American Neurological Association, American Society for Clinical Investigation Council, and American Academy of Neurology.
Explore the NIH-funded blood test using p-tau217 that predicts Alzheimer's symptom onset within 3-4 years, led by WashU researchers. Implications for trials and prevention.
Photo by Precondo CA on Unsplash
Photo by Brecht Corbeel on Unsplash
Photo by Anne Nygård on Unsplash
Photo by Kelly Sikkema on Unsplash
Photo by Markus Winkler on Unsplash
Photo by Philip Strong on Unsplash
